Chemistry:AQW-051
From HandWiki
AQW-051 also known as VQW-765 is an orally available, highly selective partial agonist of the alpha-7 nicotinic receptor (nAChR)[1][2] developed by Novartis as a central nervous system agent aimed at improving cognitive function in disorders such as schizophrenia and Alzheimer's disease, and for reducing L-Dopa–induced dyskinesias in Parkinson's disease.[1] AQW-051 had reached Phase 2 clinical trials for conditions like schizophrenia and Parkinson’s disease, but development for Alzheimer’s disease has been discontinued.[3][4]
It was later licensed it to Vanda Pharmaceuticals and who are evaluating it in phase 3 clinical trials for phobic disorders[5] and social anxiety.[6]
References
- ↑ 1.0 1.1 "AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys". Parkinsonism & Related Disorders 20 (11): 1119–1123. November 2014. doi:10.1016/j.parkreldis.2014.05.007. PMID 25172125.
- ↑ "AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation". British Journal of Pharmacology 172 (5): 1292–304. March 2015. doi:10.1111/bph.13001. PMID 25363835.
- ↑ "Task-related fMRI responses to a nicotinic acetylcholine receptor partial agonist in schizophrenia: A randomized trial". Progress in Neuro-psychopharmacology & Biological Psychiatry 71: 66–75. November 2016. doi:10.1016/j.pnpbp.2016.06.013. PMID 27371157.
- ↑ "A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia". Movement Disorders 31 (7): 1049–54. July 2016. doi:10.1002/mds.26569. PMID 26990766.
- ↑ "VQW-765". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800029640.
- ↑ "Efficacy and safety of an alpha 7-nicotinic acetylcholine receptor agonist, VQW-765, in subjects with performance anxiety: randomised, double-blind, placebo-controlled trial". The British Journal of Psychiatry : The Journal of Mental Science 227 (1): 473–480. July 2025. doi:10.1192/bjp.2025.84. PMID 40340771.
 |  |
